Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | Director | September 24, 2026 | October 05, 2026 |
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | August 10, 2026 | August 12, 2026 |
| Spectrum Brands Holdings, Inc.SPB · Entity 4515 | Director | December 12, 2025 | December 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date September 24, 2026 · Filed October 05, 2026
This filing explicitly reported no securities owned.
Amneal Pharmaceuticals, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy Limited Liability Company | 283,632 |
Reported balance
After 2026-08-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 283,632 · Balance 283,632 F1: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 283,632 shares of Class A Common Stock in the Acquisition. |
| Class A Common StockSEC Table I · non-derivative | Direct | 1,643,963 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,643,963 |
Filing footnotes · ownership attribution and instrument terms
F1: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 283,632 shares of Class A Common Stock in the Acquisition.
Spectrum Brands Holdings, Inc.
Report date December 12, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,141 |
Reported balance
After 2025-12-12 transaction · row 1
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 4,602 · Balance 22,141 F1: The Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2026 if the Reporting Person is a director of the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2026 if the Reporting Person is a director of the Issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 20:39 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 283,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-056288 · wk-form4_1786567192.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Limited Liability Company Disclosed balance after: 283,632 F1 · kind: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 283,632 shares of Class A Common Stock in the Acquisition. F1 · price: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 283,632 shares of Class A Common Stock in the Acquisition. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 34,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032922 · wk-form4_1778272004.xml · derivative · entry 2 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. F2 · derivative.expiration_date: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 34,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-032922 · wk-form4_1778272004.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,643,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2026 Filed May 8, 2026 20:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 19,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032922 · wk-form4_1778272004.xml · derivative · entry 3 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,824 Underlying: Class A Common Stock · 19,824 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 00:08 UTC | Spectrum Brands Holdings, Inc. SPB · Entity 4515 | GrantCommon Stock | 4,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001738054-25-000006 · wk-form4_1765930135.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,141 F1 · shares: The Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2026 if the Reporting Person is a director of the Issuer on such date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 94,906 | $8.02 | $761,146.12 |
DisclosureSEC source: 0001628280-25-032108 · wk-form4_1750277496.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,609,144 F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.05 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 56,426 | $8.02 | $452,536.52 |
DisclosureSEC source: 0001628280-25-030958 · wk-form4_1749759347.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,704,050 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.05 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 06, 2025 Filed May 8, 2025 22:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 34,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023966 · wk-form4_1746742630.xml · derivative · entry 3 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,819 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 05, 2025 Filed May 6, 2025 20:29 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 4,900 | $8.00 | $39,200.00 |
DisclosureSEC source: 0001628280-25-022719 · wk-form4_1746563381.xml · nonDerivative · entry 2 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,720,218 F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.01 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| May 05, 2025 Filed May 8, 2025 22:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 40,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023966 · wk-form4_1746742630.xml · derivative · entry 2 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. F2 · derivative.expiration_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. Read SEC document |
| May 05, 2025 Filed May 8, 2025 22:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 40,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-023966 · wk-form4_1746742630.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,760,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:29 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 3,768 | $8.00 | $30,144.00 |
DisclosureSEC source: 0001628280-25-022719 · wk-form4_1746563381.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,725,118 F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.01 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:12 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 80,000 | $8.30 | $664,000.00 |
DisclosureSEC source: 0001628280-25-016184 · wk-form4_1743624762.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,728,886 F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.17 to $8.43 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:12 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 80,000 | $8.90 | $712,000.00 |
DisclosureSEC source: 0001628280-25-010679 · wk-form4_1741219921.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,808,886 F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15,2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.73 to $8.98 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 80,000 | $8.14 | $651,200.00 |
DisclosureSEC source: 0001628280-25-004064 · wk-form4_1738791099.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,888,886 F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.02 to $8.28 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 62,590 | $8.01 | $501,345.90 |
DisclosureSEC source: 0001628280-25-001153 · wk-form4_1736544318.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,968,886 F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.04 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 17,410 | $8.01 | $139,454.10 |
DisclosureSEC source: 0001628280-25-000581 · wk-form4_1736198539.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,031,476 F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reports Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.06 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 22:51 UTC | Spectrum Brands Holdings, Inc. SPB · Entity 4515 | GrantCommon Stock | 2,770 | $90.26 | $250,020.20 |
DisclosureSEC source: 0000109177-24-000061 · wk-form4_1732143055.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,539 F1 · shares: Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2025 if Reporting Person is a director of the Issuer on such date. F1 · price: Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2025 if Reporting Person is a director of the Issuer on such date. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 76,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-023241 · wk-form4_1715719116.xml · derivative · entry 2 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. F2 · derivative.expiration_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 76,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023241 · wk-form4_1715719116.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,048,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 02, 2024 Filed May 6, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 40,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020741 · wk-form4_1715031344.xml · derivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,258 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:36 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GiftClass A Common Stock | 1,598,115 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-24-000011 · form4.xml · nonDerivative · entry 2 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,972,433 F2 · kind: The reporting person is a beneficiary of one of the Trusts. Following the execution of the transactions described in the preceding footnote, on January 1, 2024, the reporting person received a distribution from such Trust of 1,598,115 shares of the Class A Common Stock of the issuer. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:36 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass A Common Stock | 33,458,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-24-000011 · form4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,318 F1 · kind: The reporting person previously controlled an entity (the "Trustee") that serves as the sole trustee of certain trusts (the "Trusts") that hold, in the aggregate, 33,458,067 shares of the Class A Common Stock of the issuer. On January 1, 2024, the reporting person sold to a third party all of the issued and outstanding common stock of the Trustee. In connection therewith, the reporting person also resigned from all positions he previously held with the Trustee, effective as of January 1, 2024. As a result of these transactions, the reporting person no longer has beneficial ownership of any of the shares of Class A Common Stock of the issuer held by any trusts of which the Trustee is the sole trustee. F1 · price: The reporting person previously controlled an entity (the "Trustee") that serves as the sole trustee of certain trusts (the "Trusts") that hold, in the aggregate, 33,458,067 shares of the Class A Common Stock of the issuer. On January 1, 2024, the reporting person sold to a third party all of the issued and outstanding common stock of the Trustee. In connection therewith, the reporting person also resigned from all positions he previously held with the Trustee, effective as of January 1, 2024. As a result of these transactions, the reporting person no longer has beneficial ownership of any of the shares of Class A Common Stock of the issuer held by any trusts of which the Trustee is the sole trustee. Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 21:19 UTC | Spectrum Brands Holdings, Inc. SPB · Entity 4515 | GrantCommon Stock | 3,775 | $0.00 | $0.00 |
DisclosureSEC source: 0000109177-23-000058 · wk-form4_1701206355.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,769 F1 · shares: Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2024 if Reporting Person is a director of the Issuer on such date. F1 · price: Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2024 if Reporting Person is a director of the Issuer on such date. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 23:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass B Common Stock and Common Units · Derivative | 17,497,336 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054741 · doc4.xml · derivative · entry 3 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 17,497,336 shares Expires not disclosed F4 · security: The Issuer of the Common Units is Amneal Pharmaceuticals, LLC. F2 · derivative.exercise_price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · derivative.exercise_date: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · derivative.expiration_date: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F3 · ownership.nature: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 23:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass A Common Stock | 17,497,336 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054741 · doc4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 30,384,769 F1 · security: On November 7, 2023, Amneal Pharmaceuticals, Inc. (formerly known as Amneal NewCo Inc.) (the "Issuer") became the successor of Amneal Intermediate Inc. (formerly known as Amneal Pharmaceuticals, Inc.) ("Old PubCo") pursuant to merger transactions, in which a subsidiary of the Issuer merged with and into Old PubCo with Old PubCo surviving and, immediately following such merger, a subsidiary of the Issuer merged with and into Amneal Pharmaceuticals, LLC ("AP"), an indirect subsidiary of the Issuer, with AP surviving. The transactions resulted in the Issuer becoming a parent holding company of Old PubCo and AP. As a result of the transactions, there is a single class of stock of the Issuer outstanding, and the proportionate economic and voting rights of security holders in the Issuer are identical to the direct and indirect economic and voting rights held in Old PubCo and AP prior to the transactions. F2 · price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F3 · ownership.nature: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 80,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028733 · doc4.xml · derivative · entry 4 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 80,128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023. F4 · derivative.expiration_date: On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 80,128 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028733 · doc4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 76,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028733 · doc4.xml · derivative · entry 3 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,453 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 21:53 UTC | Spectrum Brands Holdings, Inc. SPB · Entity 4515 | GrantCommon Stock | 5,020 | $0.00 | $0.00 |
DisclosureSEC source: 0000109177-22-000046 · wf-form4_166975876860565.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,994 F1 · shares: 1. Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2023 if Reporting Person is a director of the Issuer on such date. F1 · price: 1. Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2023 if Reporting Person is a director of the Issuer on such date. Read SEC document |
| May 09, 2022 Filed May 10, 2022 23:04 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 80,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028166 · doc4.xml · derivative · entry 4 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 Underlying: Class A Common Stock · 80,128 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F4 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 08, 2022 Filed May 10, 2022 23:04 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028166 · doc4.xml · derivative · entry 3 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 35,406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On May 5, 2021 the reporting person was granted 35,406 restricted stock units vesting on May 8, 2022. F3 · derivative.expiration_date: On May 5, 2021 the reporting person was granted 35,406 restricted stock units vesting on May 8, 2022. Read SEC document |
| May 08, 2022 Filed May 10, 2022 23:04 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028166 · doc4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 50,000 | $4.21 | $210,500.00 |
DisclosureSEC source: 0001209191-21-070646 · doc4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,784 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.14 to $4.35. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:20 UTC | Spectrum Brands Holdings, Inc. SPB · Entity 4515 | GrantCommon Stock | 2,441 | $0.00 | $0.00 |
DisclosureSEC source: 0000109177-21-000101 · wf-form4_163977959973266.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,974 F1 · shares: Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2022 if the Reporting Person is a director of the Issuer on such date. Read SEC document |
| December 01, 2021 Filed Dec 1, 2023 21:15 UTC Amendment | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass A Common Stock | 3,073,298 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-23-000827 · form4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Footnote Disclosed balance after: 15,960,731 F1 · kind: On December 1, 2021, an entity controlled by the reporting person was designated as the trustee of a trust that holds 3,073,298 shares of the Class A Common Stock of the issuer. These shares were not previously reported as being beneficially owned by the reporting person due to a clerical error. The reporting person is filing this amendment to the Form 4 filed on December 20, 2021, to include the shares held by the trust in the number of shares reported as being beneficially owned by the reporting person through trusts which the reporting person may be deemed to control. As a result of the error, all Section 16 reports filed by the reporting person after December 20, 2021 understated the number of shares of the Class A Common stock of the issuer beneficially owned by the reporting person by 3,073,298 shares. All such subsequent reports are hereby updated by this amendment. F1 · price: On December 1, 2021, an entity controlled by the reporting person was designated as the trustee of a trust that holds 3,073,298 shares of the Class A Common Stock of the issuer. These shares were not previously reported as being beneficially owned by the reporting person due to a clerical error. The reporting person is filing this amendment to the Form 4 filed on December 20, 2021, to include the shares held by the trust in the number of shares reported as being beneficially owned by the reporting person through trusts which the reporting person may be deemed to control. As a result of the error, all Section 16 reports filed by the reporting person after December 20, 2021 understated the number of shares of the Class A Common stock of the issuer beneficially owned by the reporting person by 3,073,298 shares. All such subsequent reports are hereby updated by this amendment. F1 · balance_after: On December 1, 2021, an entity controlled by the reporting person was designated as the trustee of a trust that holds 3,073,298 shares of the Class A Common Stock of the issuer. These shares were not previously reported as being beneficially owned by the reporting person due to a clerical error. The reporting person is filing this amendment to the Form 4 filed on December 20, 2021, to include the shares held by the trust in the number of shares reported as being beneficially owned by the reporting person through trusts which the reporting person may be deemed to control. As a result of the error, all Section 16 reports filed by the reporting person after December 20, 2021 understated the number of shares of the Class A Common stock of the issuer beneficially owned by the reporting person by 3,073,298 shares. All such subsequent reports are hereby updated by this amendment. F2 · ownership.direct: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. F2 · ownership.nature: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 06, 2021 Filed May 7, 2021 18:09 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 46,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030813 · doc4.xml · derivative · entry 4 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 46,218 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 5, 2020 the reporting person was granted 46,218 restricted stock units vesting on May 6, 2021. F4 · derivative.expiration_date: On May 5, 2020 the reporting person was granted 46,218 restricted stock units vesting on May 6, 2021. Read SEC document |
| May 06, 2021 Filed May 7, 2021 18:09 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 46,218 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-030813 · doc4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 05, 2021 Filed May 7, 2021 18:09 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 35,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030813 · doc4.xml · derivative · entry 3 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,406 Underlying: Class A Common Stock · 35,406 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:40 UTC | Spectrum Brands Holdings, Inc. SPB · Entity 4515 | GrantCommon Stock | 3,533 | $0.00 | $0.00 |
DisclosureSEC source: 0000109177-20-000064 · wf-form4_160875944818333.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,533 F1 · shares: Reporting Person was awarded restricted stock units under the Company's 2011 Omnibus Equity Award Plan which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2021 if Reporting Person is a director of the Issuer on such date. Read SEC document |
| May 07, 2020 Filed May 7, 2020 21:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012259 · doc4.xml · derivative · entry 4 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 6, 2019, the reporting person was granted 6,459 restricted stock units vesting on May 7, 2020. F4 · derivative.expiration_date: On May 6, 2019, the reporting person was granted 6,459 restricted stock units vesting on May 7, 2020. Read SEC document |
| May 07, 2020 Filed May 7, 2020 21:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012259 · doc4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 46,218 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012259 · doc4.xml · derivative · entry 3 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,218 Underlying: Class A Common Stock · 46,218 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| March 03, 2020 Filed Mar 11, 2020 01:14 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 117,889 | $3.94 | $464,482.66 |
DisclosureSEC source: 0000899243-20-007820 · doc4.xml · nonDerivative · entry 2 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,107 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.86 to $4.00, inclusive. Read SEC document |
| March 02, 2020 Filed Mar 11, 2020 01:14 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 32,111 | $3.88 | $124,590.68 |
DisclosureSEC source: 0000899243-20-007820 · doc4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,218 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.84 to $3.90, inclusive. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | ConversionCommon Units · Derivative | 12,887,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-013997 · wf-form4_157359524653914.xml · derivative · entry 4 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,497,336 Underlying: Class A Common Stock · 12,887,433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. F3 · derivative.exercise_date: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. F3 · derivative.expiration_date: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. F1 · ownership.nature: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass B Common Stock | 12,887,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-013997 · wf-form4_157359524653914.xml · nonDerivative · entry 2 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,497,336 F2 · kind: Reflects the cancellation for no consideration of Class B Common Stock in connection with the conversion of the Common Units into shares of Class A Common Stock. F1 · ownership.nature: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | ConversionClass A Common Stock | 12,887,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-013997 · wf-form4_157359524653914.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,887,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000073 · wf-form4_155735216396679.xml · derivative · entry 4 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000073 · wf-form4_155735216396679.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.